In order to explore the potential role of identified drug targets in the pathogenesis of T2DM, we used the previously identified 7 potential “druggable” targets eQTL for T2DM as exposure data and 10 T2DM biomarkers (vitamin D, branched-chain amino acids, low-density cholesterol, triglycerides, proinsulin levels, fatty acids, glycerol, mannose, glycoprotein acetyl, and acetoacetate) and 3 clinical features (BMI, hypertension, and waist-to-hip ratio) as outcome data to further evaluate the genetic effects of potential “druggable” targets and T2DM biomarkers (Supplementary Table 6). The gene discussed is ART4; the disease is type 2 diabetes mellitus.